Silexion completes preclinical study assessing SIL204's potential for treating KRAS-driven colorectal, lung, and pancreatic cancers, targeting an over $30 billion market.
Silexion completes preclinical study assessing SIL204's potential for treating KRAS-driven colorectal, lung, and pancreatic cancers, targeting an over $30 billion market.